Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

6.68USD
20 Apr 2018
Change (% chg)

$-0.10 (-1.47%)
Prev Close
$6.78
Open
$6.72
Day's High
$6.85
Day's Low
$6.65
Volume
173,131
Avg. Vol
350,670
52-wk High
$12.49
52-wk Low
$4.32

Chart for

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $424.22
Shares Outstanding(Mil.): 63.51
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -1.23 -- --
ROI: -8.92 13.60 13.19
ROE: -36.64 15.26 15.00

BRIEF-Depomed Appoints Stan Bukofzer As Chief Medical And Scientific Officer

* DEPOMED ANNOUNCES THE APPOINTMENT OF STAN BUKOFZER, M.D. AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL AND SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

Apr 02 2018

BRIEF-Depomed Inc Files For Mixed Shelf Of Up To $300 Million‍​

* DEPOMED INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2oD3GLe) Further company coverage:

Mar 02 2018

BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52

* ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

Dec 04 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

Dec 04 2017

BRIEF-Depomed announces Q3 loss of $0.25 per share

* Depomed inc sees ‍2017 non-gaap total revenue $380 to $385 million​

Nov 07 2017

BRIEF-Depomed and Slán Medicinal Holdings announce strategic asset transactions

* Depomed and Slán Medicinal Holdings Ltd announce strategic asset transactions

Nov 07 2017

BRIEF-PDL Biopharma announces settlement agreement with Valeant

* PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement

Oct 30 2017

Earnings vs. Estimates